TABLE 4.
The correlation between the baseline metabolite levels and the reduction of clinical symptoms.
| Baseline metabolite levels | P subscore (r/p) | N subscore (r/p) | G subscore (r/p) | Total score (r/p) |
|---|---|---|---|---|
| LysoPE (20:5) | −0.47 (0.02)a | 0.11 (0.61) | −0.02 (0.93) | −0.12 (0.58) |
| LysoPE (18:3) | −0.53 (0.007)b | 0.11 (0.61) | −0.05 (0.81) | −0.14 (0.50) |
| LysoPE (16:1) | −0.14 (0.49) | 016 (0.43) | 0.004 (0.99) | 0.002 (0.99) |
| LysoPE (20:3) | −0.22 (0.30) | 0.09 (0.66) | −0.09 (0.67) | −0.09 (0.66) |
| LysoPE (22:5) | −0.42 (0.04)a | 0.12 (0.58) | −0.09 (0.68) | −0.16 (0.43) |
| LysoPE (18:2) | −0.57 (0.003) | 0.08 (0.70) | −0.10 (0.65) | −0.21 (0.33) |
| LysoPE (22:1) | −0.04 (0.85) | 0.09 (0.66) | −0.13 (0.53) | −0.09 (0.66) |
| LysoPE (22:6) | 0.03 (0.90) | 0.33 (0.11) | 0.17 (0.42) | 0.18 (0.38) |
| LysoPE (22:0) | 0.17 (0.41) | 0.19 (0.36) | 0.14 (0.52) | 0.20 (0.34) |
| LysoPC(18:0) | 0.26 (0.20) | 0.13 (0.54) | 0.12 (0.56) | 0.21 (0.32) |
| LysoPC(22:6) | 0.01 (0.97) | 0.07 (0.73) | −0.31 (0.13) | −0.20 (0.33) |
| LysoPC(20:3) | −0.13 (0.53) | −0.01 (0.98) | −0.33 (0.11) | −0.27 (0.19) |
| LysoPC(20:4) | 0.07 (0.75) | 0.03 (0.88) | −0.14 (0.49) | −0.09 (0.66) |
| LysoPC(15:0) | −0.02 (0.91) | 0.28 (0.17) | −0.05 (0.81) | 0.20 (0.93) |
| LysoPC(22:4) | −0.27 (0.19) | 0.09 (0.68) | −0.38 (0.06) | −0.32 (0.12) |
| LysoPC(17:0) | 0.20 (0.33) | 0.24 (0.26) | 0.09 (0.68) | 0.19 (0.37) |
| LysoPC(14:0) | −0.05 (0.83) | 0.09 (0.66) | −0.07 (0.75) | −0.02 (0.92) |
| LysoPC(16:1) | −0.06 (0.77) | 0.17 (0.41) | −0.14 (0.51) | −0.07 (0.75) |
| LysoPC(18:3) | −0.38 (0.06) | 0.02 (0.94) | −0.41 (0.04)* | −0.38 (0.06) |
| LysoPC(20:2) | 0.02 (0.94) | 0.12 (0.56) | −0.31 (0.13) | −0.18 (0.39) |
| LysoPC(22:2) | −0.07 (0.74) | 0.14 (0.51) | −0.16 (0.45) | −0.09 (0.68) |
| LysoPC(18:1) | −0.29 (0.16) | 0.27 (0.19) | −0.27 (0.20) | −0.22 (0.29) |
a
p < 0.05.
b
p < 0.01.